Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 631 to 645 of 1364 results for social care

  1. Public board meeting agenda and papers: September 2024

    Agenda and papers of the NICE public board meeting on 25 September 2024

  2. How we develop HealthTech guidance

    Our Medical Technologies Evaluation Programme (MTEP) evaluates new HealthTech.

  3. Office for Digital Health

    The Office for Digital Health strives to accelerate NICE's efforts to deliver innovation to the health and care system.

  4. Cost saving guidance

    health inequalities Supporting the health and care system to implement virtual wards Social care General practice - keep...

  5. Assessing the resource impact of NICE guidance

    We estimate the costs or savings (resource impact) associated with technologies and guidelines so you can plan for and implement guidance.

  6. Pegunigalsidase alfa for treating Fabry disease (TA915)

    Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.

  7. NICE guidance implementation toolkits

    guidance"}}]} NICE guidance implementation toolkits To support health and care organisations in putting evidence-based recommendations...

  8. International collaboration

    International collaboration with NICE

  9. Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]

    In development Reference number: GID-TA10832 Expected publication date: TBC

  10. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]

    In development Reference number: GID-TA11023 Expected publication date: TBC

  11. Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTG676)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders.

  12. Quality standards advisory committee

    Membership details, terms of reference and future meeting dates for our quality standards advisory committee.

  13. Quality standards advisory committee

    Membership details, terms of reference and future meeting dates for our quality standards advisory committee.

  14. Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)

    Evidence-based recommendations on onasemnogene abeparvovec (Zolgensma) for treating spinal muscular atrophy in babies.

  15. Guide to the methods of technology appraisal 2013 (PMG9)

    This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process